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In the beginning
Mr R was a 30-year-old male who was diagnosed 
with schizophrenia at the age of 19, after he presented 
with a typical combination of disorganised behaviour 
and persecutory delusions, against a background of 
daily comorbid polysubstance abuse. Owing to a pattern of frequent 
readmissions and poor treatment adherence, he was included into the 
Assertive Community Treatment (ACT) service at Stikland Hospital 
(SH) in Cape Town.
His mother (Mrs H), aged 54, was receiving treatment at the local 
clinic for major depressive disorder (MDD) and hypertension at the 
time. Shortly after her son’s inclusion into the ACT service, she had 
her first admission to SH in January 2008, 3 years after she had first 
presented to the clinic. A diagnosis of MDD with psychotic features 
was made (persecutory delusions and auditory hallucinations). 
During this admission, no extrapyramidal side-effects were seen, 
but falls on two separate occasions were reported (attributed to 
blood pressure effects of her newly initiated antipsychotics). After 
discharge, Mrs H defaulted on her medication almost immediately, 
and 3 months later the mental health nurse referred her back to 
SH with a history of having presented with psychotic features. 
The referral letter also noted that the client had ‘numerous bruises 
resulting from falls and bumping into things’. Mrs H was assessed 
at SH, found to be mildly psychotic with akathisia, but not in need 
of admission. Propranolol was prescribed for the akathisia and she 
was also included into the ACT service. As compliance on oral 
medication remained an obstacle, the depot was reboarded.
On a home visit, the ACT keyworker noted that Mrs H had 
worsening extrapyramidal side-effects (rigidity and akathisia), and 
arranged for her to be seen by the ACT consultant psychiatrist. She 
was found to have rigidity in all limbs, brisk reflexes and a bizarre gait 
with heel-toe stepping and pronation of both feet. She was also very 
restless and struggled to cooperate during the examination. The first 
available neurology outpatient appointment was in 4 months’ time at 
Tygerberg Hospital. Her typical antipsychotics were stopped and she 
was started on oral risperidone, with a view to switching her to the 
risperdal long-acting injectable. 
Mrs H missed the first appointment with neurology and was only 
seen in November 2009. She was subjected to a battery of tests and 
bloodwork, and booked for an MRI; all this was part of the standard 
work-up for difficult-to-diagnose movement disorders. Her working 
diagnosis remained that of severe side-effects owing to typical 
antipsychotics. Both the neurology notes and psychiatry notes clearly 
stated that no athetoid movements were noted on examination. 
Subsequently, the MRI in May 2010 showed only nonspecific changes.
Finally, in July 2010, at a follow-up, Mrs H tested positive for 
Huntington’s disease. 
Educating ourselves
Huntington’s disease (HD) is an autosomal dominant neuro-
degenerative disorder that exhibits a varying prevalence across ethnic 
groups. It is estimated to affect 0.01% of the white population,[1] and 
a recent meta-analysis indicated an increased prevalence in Europe, 
North America and Australia in comparison with Asian countries. [2] 
The HD mutation is located on the Huntington gene (HTT), on the 
short arm of chromosome 4. HTT contains a trinucleotide repeat 
of cytosine-adenine-guanine (CAG) base pairs. In normal subjects, 
the number of repeats is usually between 10 and 26, but in HD the 
CAG sequence is repeated >36 times, forming a mutant strand of 
Huntington (mHtt). The exact mechanism by which the altered form 
of the protein leads to the pathological changes in HD has not yet 
been determined, but it is known to target the medium spiny neurons 
of the brain.
Over the clinical course of the illness, HD patients typically exhibit 
impairment across the triad of cognitive, neurological and psychiatric 
spectra. Neurologically, the so-called Huntington’s chorea (writhing 
type movements of the limbs and other parts of the body) is the 
most common presentation. This seems to develop owing to the 
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loss of gamma-aminobutyric acid (GABA) 
inhibitory neurons in the caudate nucleus 
and the globus pallidus, while cognitively, 
HD patients typically develop subcortical 
dementia over time owing to the loss of 
acetylcholine-secreting neurons in the 
cerebral cortex. [3] The psychiatric spectrum is 
more varied than the cognitive, neurological 
and psychiatric spectra, with ~35 - 75% of 
HD patients developing symptomatology at 
some stage of the disease. [4-6] Most commonly, 
patients present with personality changes 
such as irritability, aggression and apathy, 
while depression has a lifetime prevalence 
of 39%.[7] In contrast to popular belief, the 
psychiatric symptoms may precede the onset 
of the movement disorder or dementia, 
and in fact, HD patients often present to 
psychiatric services first. 
The typical age of onset is in the late thirties 
to early forties, but a juvenile variant is also 
well described (also known as Westphal variant 
HD or akinetic-rigid HD). The number of 
repeats of the CAG trinucleotide has been 
shown to inversely correlate with the age 
of onset of symptoms; the more repeats the 
parent has, the more unstable the replication 
process becomes, the higher the chance that 
the child will inherit a longer expansion with 
a possible earlier onset of symptoms (genetic 
anticipation).
The next step
Guidelines for the molecular genetics 
predictive test in Huntington’s disease were 
published in 1994 after the introduction 
of direct mutation analysis.[8] These were 
subsequently used by the University of Cape 
Town to instruct the development of the 
predictive testing protocol that has been 
implemented in the Western Cape Province. 
According to the protocol, predictive testing 
is considered when a person is asymptomatic 
and has a family history of confirmed HD. 
However, when a patient does show signs 
or symptoms indicative of the onset of this 
disease, predictive testing no longer applies; 
rather, testing is done for diagnostic purposes. 
The rest of this article focuses on the ease 
of use of such a protocol in a developing 
world setting, using our own experience as an 
illustration. Difficulties encountered during this 
process, suggestions for possible improvements 
as well the ethical considerations that arise 
from managing such clients will form part of 
the discussion. Written consent was obtained 
from all participants mentioned and the 
final manuscript was also submitted to the 
Stellenbosch University Health Research 
Ethics Committee. 
Diagnostic v. predictive testing
After the diagnosis of Mrs H, the option of 
genetic testing was discussed with Mr R as he 
was psychiatrically stable. He subsequently 
tested positive for Huntington’s disease, with 
44 CAG repeats in comparison with his 
mother’s 42. 
In a patient (such as Mr R) who presents 
with psychosis, making a decision as to 
the applicability of predictive testing could 
pose an ethical dilemma. Does this patient 
present with schizophrenia as a separate 
disease process or are the symptoms related 
to the pathological changes of HD? If the 
answer to the former is yes, then the patient 
should be regarded as asymptomatic (also 
termed presymptomatic) and he/she should 
proceed with the process of counselling for 
predictive testing according to the protocol. 
If the symptoms are judged to possibly be 
part of the presentation of HD, the patient is 
regarded as symptomatic and the tests could 
be done diagnostically. 
Available data suggest that 5 - 25% of 
HD patients will present with psychotic 
features,[1,7] and that the likelihood of such 
a presentation is increased when the HD 
patient has a family member with HD who 
also presented with psychosis.[7] 
Three main theories exist as to why some 
HD patients present with psychosis while 
others do not: (i) genetically, these patients 
have a different subtype of HD,[7] possibly 
linked to the length of the CAG repeats;[9,10] 
(ii) cooccurrence in a ‘vulnerable’ brain[7] 
and (iii) developmental effect due to the 
stress of growing up in a disrupted family 
structure secondary to the presence of serious 
illness, of which one has a 50% chance of 
developing. [11-13] 
Currently, although we are unable to 
distinguish clinically between the psychosis 
of HD and schizophrenia, there are various 
possible pointers. A recent review on 
secondary psychosis suggests that several 
questions can be asked to determine whether 
the psychosis is as a result of a general medical 
condition (GMC).[14] These include questions 
on atypicality of presentation as well as 
temporal and/or physiological relationship 
to a GMC and/or substances. Additionally, 
primary illness factors such as age of onset, 
family history, outcomes and characteristic 
findings on special investigations should 
always be considered.
It could be argued that there is no 
immediate benefit for the patient 
presenting with psychosis alone to know 
that he/she will develop HD, as the main 
psychopharmacological management will 
not differ. Therefore, the predictive rather 
than diagnostic testing option should be 
followed. However, early diagnosis could 
have advantages. Choice of antipsychotic 
is important, as both haloperidol and 
risperidone have been shown to slow down 
the progression of the striatal dysfunction 
in HD clients.[15-17] Multidisciplinary team 
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Fig. 1. Genogram of Mr R’s family showing affected family members.
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predictive testing) as well as access to resources not available within 
the mental health system can be offered.
In the case of Mr R, he had a parent with confirmed HD, was 
deemed to be symptomatic and was therefore tested after informed 
consent was obtained. In spite of numerous post-test counselling 
sessions, Mr R’s insight remained very limited. Seen in overview, in all 
likelihood his ability to make an informed decision about predictive 
testing was significantly impaired.
Involving the rest of the family
A family meeting with the treating doctor was arranged where Mrs 
H’s mother (Mrs SG) was present, and based on her information, a 
genogram was constructed (Fig. 1).
Mrs SG gave the history that her husband (Mr HG) had a condition 
(‘the clumsy disease’) that he developed later in his life. According to 
her, he was diagnosed with a form of seizure disorder. Another one of 
her daughters, Mrs J, was admitted to an old-age home at a young age 
with a diagnosis of Parkinson’s disease, and Mrs H believed she also 
had ‘the clumsy disease’. 
Mrs J was visited and found to display the typical choreiform 
movements of HD. She was also at an advanced stage of dementia and, 
regarding her as HD symptomatic, we obtained informed consent 
from her legal guardian for diagnostic testing; she tested positive with 
43 CAG repeats.
Attempting predictive testing
A family meeting with the genetic counsellor was planned; as per the 
protocol a genetic counsellor from Tygerberg Hospital was requested 
to facilitate the session in order to ensure provision of adequate 
information on HD and psychosocial support.
The family had no telephone and contact could only be established 
via home visits, done jointly by the ACT keyworker and doctor. Flyers 
bearing the details of the meeting were also left at their home.
In an attempt to make it more accessible, the meeting was held at the 
local community healthcare centre. Only Mrs H’s five children attended 
this meeting. Only two of the five siblings were eligible for predictive 
testing as the other three were under the age of 18 years (according 
to the protocol the age of consent is 18); Taking into account that the 
teenage pregnancy rate in South Africa (SA) is 54/1 000 (WHO/Global 
Health Observatory Data Repository[18]), this decision should likely be 
revisited as family planning is vital in HD.
The second meeting with both eligible siblings was scheduled just 
over 2 months after the initial meeting. Mrs JU had married a few 
months prior to the meeting and was pregnant, while Ms JL was 
unmarried but had a 2-year-old daughter. Mrs JU had discussed 
predictive testing with her husband and, even though he encouraged 
her to do so, decided against testing. Her reasons for doing so were 
mainly that she thought that she wouldn’t be able to handle a positive 
result and the ‘constant waiting’ for the symptoms to appear. Ms JL 
decided to go ahead mainly to determine if her child was also at risk, 
but also because she ‘would rather know than not know’. A follow-up 
appointment was arranged with Ms JL for an individual session. She 
was also asked to identify someone as a support partner (as per the 
protocol).
Ms JL did not attend the follow-up at the end of January 2012, 
indicating that she could not get off from work. Another session 
could only be arranged for early in April as the genetic counsellor was 
unavailable. Once again, Ms JL failed to attend. The counsellor then 
made contact and explicitly asked if she had doubts about testing; she 
affirmed this. Further counselling and predictive testing was thus put 
on hold, pending notice from Ms JL.
Barriers to effective protocol implementation in 
a developing world setting
Resources
Futter et al.[19] concluded that factors such as low income and education 
level contribute to poor access to predictive testing centres and 
programmes in the Western Cape. The challenges experienced during 
our process are not unique to HD clients but are specifically frustrating 
when one is trying to work within the confines of a structured 
protocol. The family did not have a telephone or access to electronic 
communication so they could only be reached by means of the ACT 
team performing home visits. Obviously, this resulted in delays in 
arranging follow-up appointments. In addition, the family also made 
use of public transport and could not always attend meetings owing to 
the lack of funds or unpredictability of the transport system. 
Genetic counsellors
According to the international protocol, a multidisciplinary team 
should be involved in the process of predictive testing, including 
a neurologist, clinical psychologist and a genetic counsellor. The 
counsellor’s role is to inform the client about the disease, its 
inheritance pattern and therefore the client’s risk of HD, to give as 
much information as possible about the advantages and disadvantages 
of predictive testing and to prepare them for the implications and 
outcome of the result, taking into consideration their psychosocial 
circumstances. The process is supposed to create an environment 
where the client has sufficient information, time and support to make 
an informed decision about predictive testing.
Currently, there are only 18 registered genetic counsellors (of 
which 3 are interns) in SA. According to the Genetic Service Plan 
for SA, the suggested genetic counsellor-to-person ratio is 1:500 000, 
which translates to a recommended >100 genetic counsellors in SA 
and >11 counsellors for the Western Cape. At present, there are only 
two genetic counsellor posts available in state practice in the Western 
Cape, both of which are part-time contract posts (4 days/week). The 
Gauteng Province has four permanent posts and KwaZulu-Natal one. 
In comparison, the USA has 2 500 registered genetic counsellors.
It would therefore come as no surprise that the genetic counsellor 
helping us had very limited availability. Adding to that the practical 
difficulties experienced communicating with the family, one has a 
clearer picture as to why the whole process was stretched over such 
an extended period of time.
Coordination of services
In most parts of the country, HD clients do not have easy access to 
coordinated services. Mr R’s treating doctor was based at SH, the 
genetic counsellor at Tygerberg Hospital and the family had to be seen 
at the local community health centre in their area. The examination 
room used for this was not really designed to host a therapeutic 
intervention. Certainly these factors contributed to the difficulty in 
keeping the family engaged in the process. 
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Conclusion
The HD predictive testing programme in SA has previously been 
scrutinised, with numerous suggestions made to try to overcome 
some of the identified difficulties.[19] Our experience of the 
process once again highlighted many frustrations. Lack of some 
basic resources made adherence to goals of the protocol virtually 
impossible. It was very difficult to try to maintain a balance 
between giving the client enough time to process information, 
contemplate and make an informed decision about testing, and 
keeping the client engaged to prevent him/her from becoming lost 
to follow-up.
More posts for properly trained genetic counsellors are vital, and 
ideally, designated teams should be readily accessible at primary care 
level. One possible solution would be the implementation of mobile 
clinics. 
Ultimately the protocol should serve to make the process as 
meaningful as possible to every client, and thus it should be more 
adaptable to the client’s unique situation and needs.
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